After quietly huddling in 2015 while it filled out its C-suite and lined up a manufacturing deal, Tizona Therapeutics Inc. went on the offense with a fast break into immunotherapy, scoring a $43 million series B round. The financing was co-led by Abingworth and Canaan Partners with investments from Lightstone Ventures and existing series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and Interwest Partners. Read More
Immunomet Therapeutics Inc.’s chief scientific officer, Sanghee Yoo, told BioWorld Today that $5.2 million in series A money will take the company to the start of phase I trials with oxidative phosphorylation (OXPHOS) inhibitor IM156 and fund operations into 2017, though the firm has “not provided specific details” on an immuno-oncology program, also in the pipeline, he said. Read More
The U.S. Department of Health and Human Services (HHS) will not issue new guidelines for the NIH to march in on patent rights because of high drug prices. Read More
SAN FRANCISCO – Despite growing appreciation for many benefits of personalized medicine, earning it new attention in health care institutions and Washington, progress in the field continues to be decidedly mixed, according to speakers at the Molecular Medicine Tri-Con meeting this week. Read More
TOKYO – Japan has made great strides in speeding drug and device approvals, but there are concerns that fewer products are coming to market despite the visible regulatory improvements over the past decade. Read More
HONG KONG – In a move that has once again highlighted concerns over the quality of some made-in-China drugs and raw materials, French regulators have raised questions regarding heparin made by a mainland company. Read More
Cardiome Pharma Corp., of Vancouver, British Columbia, filed a prospectus supplement pertaining to sales under a January purchase agreement with Lincoln Park Capital Fund LLC (LPC) and a separate prospectus supplement pertaining to sales under a February at-the-market (ATM) sales agreement with MLV & Co. LLC. Read More
Redhill Biopharma Ltd., of Tel Aviv, Israel, reported final results from the first phase III study (ERADICATE Hp) of RHB-105, a fixed-dose combination of two antibiotics and a proton pump inhibitor, for the eradication of H. pylori. Read More
Bio-Path Holdings Inc., of Houston, said the University of Texas MD Anderson Cancer Center will evaluate Bio-Path’s pipeline for its ability to modulate pancreatic cancer through a sponsored research agreement. Read More
